Drug Profile
HL 1550
Alternative Names: HL1550Latest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator Handok Inc
- Class Antihyperglycaemics; Antihyperlipidaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diabetes mellitus; Hyperlipidaemia
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for preclinical development in Diabetes-mellitus in South Korea
- 28 Sep 2021 No recent reports of development identified for preclinical development in Hyperlipidaemia in South Korea
- 08 Aug 2017 Preclinical trials in Diabetes mellitus in South Korea (unspecified route)